Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616924 · ClinicalTrials.gov registry record · Phase 3
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
A Phase 3 study, sponsored by RedHill Biopharma Limited.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT04616924 is a Phase 3 study that was terminated before completion, run by RedHill Biopharma Limited. The registered enrollment target is 12 participants.
The verdict
NCT04616924, a Phase 3 study, was terminated before completion, sponsored by RedHill Biopharma Limited.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung infection.
Interventions
- DRUG Placebo
- DRUG RHB-204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2023-08-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04616924
The ClinicalTrials.gov registry entry for NCT04616924 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04616924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04616924 about?
NCT04616924 is a clinical study titled "RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease". A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung infection.
What is the current status of trial NCT04616924?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2020-12-01. Estimated completion is 2023-08-28.
What interventions are being tested in trial NCT04616924?
The interventions under investigation include: Placebo (DRUG), RHB-204 (DRUG).
Who is sponsoring clinical trial NCT04616924?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.